Calidi’s proprietary stem cell-based technologies NeuroNova (NNV) and SuperNova (SNV), have been designed to target numerous cancer indications unresponsive to many currently available treatments:
NeuroNova (NNV): Composed of immortalized neural stem cells (NSC) loaded with oncolytic adenovirus, for the treatment of patients with glioblastoma (GBM), an aggressive cancer in the brain or spinal cord. An open-label, Phase 1, dose-escalation clinical trial in patients with newly diagnosed high-grade gliomas has been completed, establishing the safety and signals of efficacy in patients with newly diagnosed glioblastoma (GBM). Clinical trial results were published in the prestigious journal, The Lancet Oncology, in the article, “Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial, (Fares et al. June 2021).
SuperNova (SNV): Composed of adipose-derived mesenchymal stem cells (AD-MSC) loaded with oncolytic vaccinia virus, for the treatment of patients with advanced solid tumors. A physician-sponsored Phase 1 clinical trial was completed using autologous adipose-derived stromal cells, documenting excellent safety, and signaling efficacy in 24 patients with advanced solid tumors and two patients with acute myeloid leukemia (AML). Clinical trial results were published in the Journal of Translational Medicine, in the article, “First‑in‑human study of TK‑positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells,” (Minev et al. August 2019).